Breast Cancer Research and Treatment

, Volume 36, Issue 2, pp 237–251

Antibody-directed targeting of the vasculature of solid tumors

  • Philip E. Thorpe
  • Francis J. Burrows

DOI: 10.1007/BF00666044

Cite this article as:
Thorpe, P.E. & Burrows, F.J. Breast Cancer Res Tr (1995) 36: 237. doi:10.1007/BF00666044


An attractive strategy for the therapy of carcinomas and other solid tumors would be to target cytotoxic agents or host immune effectors to the endothelial cells of the tumor vasculature rather than to the tumor cells themselves. The key advantage of this approach is that the endothelial cells are freely accessible through the blood whereas the tumor cells are, for the most part, inaccessible. Also, endothelial cells are similar in different tumors, making it feasible to develop a single reagent for treating numerous types of cancer. In this chapter, we review progress in this “vascular targeting” approach, from the validation of the concept in a mouse model to the characterization of the TEC-11 antibody against endoglin, an endothelial cell proliferation marker that is upregulated on endothelial cells in miscellaneous human solid tumors. In addition, we review other tumor endothelial cell markers that are candidates for vascular targeting in man.

Key words

endothelial cells monoclonal antibodies solid tumors TEC-11 antibody therapy vascular targeting 

Copyright information

© Kluwer Academic Publishers 1995

Authors and Affiliations

  • Philip E. Thorpe
    • 1
  • Francis J. Burrows
    • 1
  1. 1.Harold C. Simmons Comprehensive Cancer CenterUniversity of Texas Southwestern Medical CenterDallasUSA

Personalised recommendations